Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases
HUCHON, Melanie
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
Voir plus >
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
HUCHON, Melanie
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
BÉAVOGUI, Abdoul Habib
Centre National de Formation et de Recherche en Santé Rurale [Maférinyah, Guinée] [CNFRSR]
Centre National de Formation et de Recherche en Santé Rurale [Maférinyah, Guinée] [CNFRSR]
THIÉBAUT, Rodolphe
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
RICHERT, Laura
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
< Réduire
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
Langue
EN
Article de revue
Ce document a été publié dans
Nature Communications. 2024-09-03, vol. 15, n° 1, p. 7666
Résumé en anglais
Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck’s Ervebo (rVSV-ZEBOV) and Johnson & Johnson’s two-dose combination (Ad26.ZEBOV/ ...Lire la suite >
Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck’s Ervebo (rVSV-ZEBOV) and Johnson & Johnson’s two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year follow-up of the PREVAC randomized trial (NCT02876328), we report the results of the immunology ancillary study of the trial. The primary endpoint is to evaluate long-term memory T-cell responses induced by three vaccine regimens: Ad26–MVA, rVSV, and rVSV–booster. Polyfunctional EBOV-specific CD4+ T-cell responses increase after Ad26 priming and are further boosted by MVA, whereas minimal responses are observed in the rVSV groups, declining after one year. In-vitro expansion for eight days show sustained EBOV-specific T-cell responses for up to 60 months post-prime vaccination with both Ad26-MVA and rVSV, with no decline. Cytokine production analysis identify shared biomarkers between the Ad26-MVA and rVSV groups. In secondary endpoint, we observed an elevation of pro-inflammatory cytokines at Day 7 in the rVSV group. Finally, we establish a correlation between EBOV-specific T-cell responses and anti-EBOV IgG responses. Our findings can guide booster vaccination recommendations and help identify populations likely to benefit from revaccination.< Réduire
Unités de recherche
Publications correspondantes
Affichage des publications liées par titre, auteur, créateur et discipline
-
Broadband Multi-wavelength Properties of M87 during the 2017 Event Horizon Telescope Campaign
ALGABA, J.C.; ANCZARSKI, J.; ASADA, K. ...(Astrophys.J.Lett.. vol. 911, n° 1, pp. L11, 2021)Article de revue -
STATE OF THE CLIMATE IN 2011 Special Supplement to the Bulletin of the American Meteorological Society Vol. 93, No. 7, July 2012
CRETAUX, Jean-Francois; SWEET, William; CROUCH, Jake ...(Bulletin of the American Meteorological Society. vol. 93, n° 7, S, pp. S1-S263, 2012)Article de revue -
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
HEIER, Jeffrey S; LAD, Eleonora M.; HOLZ, Frank G. ...(The Lancet. vol. 402, n° 10411, pp. 1434-1448, 2023-10-21)Article de revue